Search

Your search keyword '"Zaorsky, Nicholas G."' showing total 736 results
Start Over Author "Zaorsky, Nicholas G."
736 results on '"Zaorsky, Nicholas G."'

151. Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice

Author

Sanmamed, Noelia, primary, Glicksman, Rachel M., additional, Herrera-Caceres, Jaime, additional, Lehrer, Eric J., additional, Heaton, Jaqueline, additional, Hansen, Aaron R., additional, Chung, Peter, additional, Fleshner, Neil E., additional, Den, Robert B., additional, Zaorsky, Nicholas G., additional, and Berlin, Alejandro, additional

Published
2020
Full Text
View/download PDF

152. Quantitation and predictors of short-term mortality following extrapleural pneumonectomy, pleurectomy/decortication, and nonoperative management for malignant pleural mesothelioma

Author

Wright, Christopher, primary, Verma, Vivek, additional, Barsky, Andrew R., additional, Haque, Waqar, additional, Polamraju, Praveen V., additional, Ludmir, Ethan B., additional, Zaorsky, Nicholas G., additional, Lehrer, Eric J., additional, Trifiletti, Daniel M., additional, Grover, Surbhi, additional, Friedberg, Joseph S., additional, and Simone II, Charles B., additional

Published
2020
Full Text
View/download PDF

153. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19

Author

Zaorsky, Nicholas G., primary, Yu, James B., additional, McBride, Sean M., additional, Dess, Robert T., additional, Jackson, William C., additional, Mahal, Brandon A., additional, Chen, Ronald, additional, Choudhury, Ananya, additional, Henry, Ann, additional, Syndikus, Isabel, additional, Mitin, Timur, additional, Tree, Alison, additional, Kishan, Amar U., additional, and Spratt, Daniel E., additional

Published
2020
Full Text
View/download PDF

154. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients

Author

Levin-Epstein, Rebecca, primary, Cook, Ryan R., additional, Wong, J. Karen, additional, Stock, Richard G., additional, Jeffrey Demanes, D., additional, Collins, Sean P., additional, Aghdam, Nima, additional, Suy, Simeng, additional, Mantz, Constantine, additional, Katz, Alan J., additional, Nickols, Nicholas G., additional, Miszczyk, Leszek, additional, Napieralska, Aleksandra, additional, Namysl-Kaletka, Agnieszka, additional, Prionas, Nicholas D., additional, Bagshaw, Hilary, additional, Buyyounouski, Mark K., additional, Cao, Minsong, additional, Mahal, Brandon A., additional, Shabsovich, David, additional, Dang, Audrey, additional, Yuan, Ye, additional, Rettig, Matthew B., additional, Chang, Albert J., additional, Jackson, William C., additional, Spratt, Daniel E., additional, Lehrer, Eric J., additional, Zaorsky, Nicholas G., additional, Kupelian, Patrick A., additional, Steinberg, Michael L., additional, Horwitz, Eric M., additional, Jiang, Naomi Y., additional, and Kishan, Amar U., additional

Published
2020
Full Text
View/download PDF

158. Current treatment and future directions in the management of anal cancer.

Author

Tchelebi, Leila T., Eng, Cathy, Messick, Craig A., Hong, Theodore S., Ludmir, Ethan B., Kachnic, Lisa A., and Zaorsky, Nicholas G.

Subjects
ANAL cancer, IMMUNE checkpoint inhibitors, NEOADJUVANT chemotherapy, INDUCTION chemotherapy, RADIATION injuries, RADIATION doses
Abstract

Although rare, the rate of squamous cell carcinoma of the anus (SCCA) is rising globally. Most patients present with nonmetastatic disease and are curable with appropriate treatment, which has evolved significantly over the last several decades. Before the 1970s, SCCA was managed with radical surgery, resulting in a permanent colostomy. Researchers found that preoperative treatment with chemotherapy and concurrent radiation could achieve a pathologic complete response. After this observation, definitive therapy shifted from radical surgery to sphincter‐preserving chemoradiation. Investigations into the necessity of chemotherapy and the optimal regimen found that chemotherapy with mitomycin‐C and 5‐fluorouracil is required for cure. Further studies evaluating the addition of induction or maintenance chemotherapy, monoclonal antibody therapy, or higher radiation doses have demonstrated no significant benefit to disease control. Advanced radiation delivery with intensity‐modulated radiotherapy techniques is now considered the standard of care because of its prospectively determined, favorable acute toxicity profile compared with 3‐dimensional conformal radiation. It is important to note that chemoradiation treatment response may be slow (up to 26 weeks) and should be assessed through serial clinical examinations. Today, surgical management of SCCA is reserved only for the lowest risk, early stage tumors or for recurrent/persistent disease. Current studies are evaluating radiation dose de‐escalation in early stage disease and radiation dose escalation and the addition of immune checkpoint inhibitors in locally advanced cancers. In reviewing how and why modern‐day treatment of SCCA was established, the objective of this report is to reenforce adherence to current treatment paradigms to assure the best possible outcomes for patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

159. Pan‐cancer analysis of prognostic metastatic phenotypes.

Author

Zaorsky, Nicholas G., Wang, Xi, Garrett, Sara M., Lehrer, Eric J., Lin, Christine, DeGraff, David J., Spratt, Daniel E., Trifiletti, Daniel M., Kishan, Amar U., Showalter, Timothy N., Park, Henry S., Yang, Jonathan T., Chinchilli, Vernon M., and Wang, Ming

Subjects
MELANOMA, PROPORTIONAL hazards models, OVERALL survival, PHENOTYPES, SURVIVAL rate, BREAST cancer
Abstract

Although cancer is highly heterogeneous, all metastatic cancer is considered American Joint Committee on Cancer (AJCC) Stage IV disease. The purpose of this project was to redefine staging of metastatic cancer. Internal validation of nationally representative patient data from the National Cancer Database (n = 461 357; 2010‐2013), and external validation using the Surveillance, Epidemiology and End Results database (n = 106 595; 2014‐2015) were assessed using the concordance index for evaluation of survival prediction. A Cox proportional hazards model was used for overall survival by considering identified phenotypes (latent classes) and other confounding variables. Latent class analysis was performed for phenotype identification, where Bayesian information criterion (BIC) and sample‐size‐adjusted BIC were used to select the optimal number of distinct clusters. Kappa coefficients assessed external cluster validation. Latent class analysis identified five metastatic phenotypes with differences in overall survival (P <.0001): (Stage IVA) nearly exclusive bone‐only metastases (n = 59 049, 12.8%; median survival 12.7 months; common in lung, breast and prostate cancers); (IVB) predominant lung metastases (n = 62 491, 13.5%; 11.4 months; common in breast, stomach, kidney, ovary, uterus, thyroid, cervix and soft tissue cancers); (IVC) predominant liver/lung metastases (n = 130 014, 28.2%; 7.0 months; common in colorectum, pancreatic, lung, esophagus and stomach cancers); (IVD) bone/liver/lung metastases predominant over brain (n = 61 004, 13.2%; 5.9 months; common in lung and breast cancers); and (IVE) brain/lung metastases predominant over bone/liver (n = 148 799, 32.3%; 5.7 months; lung cancer and melanoma). Long‐term survivors were identified, particularly in Stages IVA‐B. A pan‐cancer nomogram model to predict survival (STARS: site, tumor, age, race, sex) was created, validated and provides 13% better prognostication than AJCC: 1‐month concordance index of 0.67 (95% confidence interval [CI]: 0.66‐0.67) vs 0.61 (95% CI: 0.60‐0.61). STARS is simple, uses easily accessible variables, better prognosticates survival outcomes and provides a platform to develop novel metastasis‐directed clinical trials. What's new? Metastatic cancer is typically fatal, but survival can range from weeks to years. Currently, however, there is only one category of stage IV cancer; thus, prognostication is unreliable. To better reflect the heterogeneity of stage IV cancers, these authors created STARS, a pan‐cancer staging system. STARS stands for "Site, Tumor, Age, Race, Sex," and for prognosis, STARS was more accurate than AJCC staging. STARS is relatively inexpensive, as it relies on readily available clinical data, making it accessible to communities worldwide. It also provides a platform for developing clinical trials for therapies against metastatic disease. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

165. Fatal heart disease among cancer patients

Author

Stoltzfus, Kelsey C., primary, Zhang, Ying, additional, Sturgeon, Kathleen, additional, Sinoway, Lawrence I., additional, Trifiletti, Daniel M., additional, Chinchilli, Vernon M., additional, and Zaorsky, Nicholas G., additional

Published
2020
Full Text
View/download PDF

166. Long‐term causes of death among pediatric patients with cancer

Author

Horn, Samantha R., primary, Stoltzfus, Kelsey C., additional, Mackley, Heath B., additional, Lehrer, Eric J., additional, Zhou, Shouhao, additional, Dandekar, Smita C., additional, Fox, Edward J., additional, Rizk, Elias B., additional, Trifiletti, Daniel M., additional, Rao, Pooja M., additional, and Zaorsky, Nicholas G., additional

Published
2020
Full Text
View/download PDF

171. Epidemiology of synchronous brain metastases

Author

Singh, Raj, primary, Stoltzfus, Kelsey C, primary, Chen, Hanbo, primary, Louie, Alexander V, primary, Lehrer, Eric J, primary, Horn, Samantha R, primary, Palmer, Joshua D, primary, Trifiletti, Daniel M, primary, Brown, Paul D, primary, and Zaorsky, Nicholas G, primary

Published
2020
Full Text
View/download PDF

175. Risk‐adapted stereotactic body radiation therapy for central and ultra‐central early‐stage inoperable non‐small cell lung cancer

Author

Meng, Mao‐Bin, primary, Wang, Huan‐Huan, additional, Zaorsky, Nicholas G., additional, Sun, Bing‐Shen, additional, Zhu, Lei, additional, Song, Yong‐Chun, additional, Li, Feng‐Tong, additional, Dong, Yang, additional, Wang, Jing‐Sheng, additional, Chen, Hua‐Ming, additional, Yu, Xu‐Yao, additional, and Yuan, Zhi‐Yong, additional

Published
2019
Full Text
View/download PDF

191. Splenic irradiation for splenomegaly: a systematic review and meta-analysis

Author

Zaorsky, Nicholas G, Williams, Graeme R, Barta, Stefan, Esnaola, Nestor, Kropf, Patricia L., Hayes, Shelly B, and Meyer, Joshua E

Subjects
Treatment Outcome, Radiotherapy, Hematologic Neoplasms, Patient Selection, Splenomegaly, Humans, Dose Fractionation, Radiation, Middle Aged, Article, Spleen, Aged
Abstract

Splenic irradiation (SI) is a palliative treatment option for symptomatic splenomegaly (i.e. for pain, early satiety, pancytopenia from sequestration) secondary to hematologic malignancies and disorders. The purpose of the current article is to review the literature on SI for hematologic malignancies and disorders, including: (1) patient selection and optimal technique; (2) efficacy of SI; and (3) toxicities of SI. PICOS/PRISMA methods are used to select 27 articles including 766 courses of SI for 486 patients from 1960 to 2016. The most common cancers treated included chronic lymphocytic leukemia and myeloproliferative disorders; the most common regimen was 10 Gy in 1 Gy fractions over two weeks, and 27% of patients received retreatment. A partial or complete response (for symptoms, lab abnormalities) was obtained in 85–90% of treated patients, and 30% were retreated within 6–12 months. There was no correlation between biologically equivalent dose of radiation therapy and response duration, pain relief, spleen reduction, or cytopenia improvement (r2 all

Published
2016

193. Use of Decipher Prostate Biopsy Test in Patients with Favorable-risk Disease Undergoing Conservative Management or Radical Prostatectomy in the Surveillance, Epidemiology, and End Results Registry

Author

Zhu, Alec, Proudfoot, James A., Davicioni, Elai, Ross, Ashley E., Petkov, Valentina I., Bonds, Sarah, Schussler, Nicki, Zaorsky, Nicholas G., Jia, Angela Y., Spratt, Daniel E., Schaeffer, Edward M., Liu, Yang, Strasser, Mary O., and Hu, Jim C.

Abstract

Genomic classifier (GC) testing is associated with greater usage of conservative management in men with favorable-risk prostate cancer. Additionally, GC testing at biopsy may provide greater prognostic value than tumor volume alone.

Published
2024
Full Text
View/download PDF

194. Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney

Author

Tan, Vivian S., Correa, Rohann J.M., Warner, Andrew, Ali, Muhammad, Muacevic, Alexander, Ponsky, Lee, Ellis, Rodney J., Lo, Simon S., Onishi, Hiroshi, Swaminath, Anand, Suk Kwon, Young, Morgan, Scott C., Cury, Fabio L., Teh, Bin S., Mahadevan, Anand, Kaplan, Irving D., Chu, William, Hannan, Raquibul, Staehler, Michael, Zaorsky, Nicholas G., Louie, Alexander V., and Siva, Shankar

Abstract

With long-term follow-up, stereotactic ablative radiotherapy (SABR) yields moderate long-term renal function decline and low dialysis rates even in patients with a solitary kidney. SABR thus represents a promising noninvasive, nephron-sparing option for patients with localized renal cell carcinoma.

Published
2024
Full Text
View/download PDF

196. Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis In Vitro and In Vivo

Author

Wang, Huan-Huan, primary, Wu, Zhi-Qiang, additional, Qian, Dong, additional, Zaorsky, Nicholas G., additional, Qiu, Ming-Han, additional, Cheng, Jing-Jing, additional, Jiang, Chao, additional, Wang, Juan, additional, Zeng, Xian-Liang, additional, Liu, Chun-Lei, additional, Tian, Li-Jun, additional, Ying, Guo-Guang, additional, Meng, Mao-Bin, additional, Hao, Xi-Shan, additional, and Yuan, Zhi-Yong, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results